OUR NEWS

Clare Ventures proudly joins the seed round via Icehouse Ventures, supporting the incredible team at Familiar Therapeutics as they set to translate proven human medicines into novel therapeutics and diagnostics for companion animals. Founder Dr Elizabeth Iorns received the kind of news every pet owner dreads when her French Bulldog, Lily, had been diagnosed with a terminal brain tumor. As a cancer biologist who had spent her career at the frontier of human oncology, Elizabeth knew what modern targeted therapy could do. But for canine glioma, no such option existed, so Familiar Therapeutics was born!

Clare Ventures portfolio partner and precision fermentation company Daisy Lab has announced its acquisition by global industrial biotechnology group Mycofeast, connecting New Zealand-developed dairy protein technology with international R&D, manufacturing and commercial capability. The acquisition signals Clare Ventures' first successful exit.

AMCVT, Anna Stuck’s family office spanning Clare Foundation and Clare Ventures is the only New Zealand member of the 2X Global network, attended the 2x Global Summit, anchored by the theme of ‘Grounded Capital, Global Partners'.

AMCVT, Anna Stuck’s Family Office which encompasses Clare Ventures, has today been announced as the newest member of 2XGlobal, a global network and field-building organisation for investors, capital providers, and intermediaries working in public and private markets, across both developed and emerging economies. AMCVT is also the only New Zealand based member, adding to the […]

Clare Ventures is proud to be join the debut fund at Scale Investors, Australia’s First Women-Led VC Fund backing Women-Led Startups. Founded in 2013 as a gender-lens syndicate, Scale Investors launched its first venture capital fund in 2025, with the focus intentionally shifting  from the Gender Investment Gap to the Gender Innovation Gap.

Clare Ventures' portfolio partner Baymatob has successfully closed a major funding round which is set to accelerate their entry into the US market.

The Sydney-based company is now involved in U.S. clinical trials, as well as trials at the Royal North Shore and Royal Hospital for Women in Sydney for their Oli device which was awarded a ‘Breakthrough Device Designation’ by the FDA, in 2021.

Clare Ventures is proud to announce our investment in E-Leviate, through Outset Ventures, signaling a big step forward for this incredible company which is tackling some of the most common yet underserved conditions in women’s health.

Kai's Education has secured NZD $1.5 million in investment to support its expansion in the United States, with the funding round expected to increase to NZD $2.346 million as interest grows.

The Auckland-based educational technology company specialises in screen-free coding tools designed for neurodiverse learners. By working directly with school districts, it aims to embed Universal Design Learning (UDL) practices in American schools.